Beigene
Beigene, a leading biotechnology company headquartered in China (CN), is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2010, Beigene has rapidly expanded its operations across major regions, including North America, Europe, and Asia, establishing a strong global presence in the biopharmaceutical industry. The company is renowned for its robust pipeline of targeted therapies and immuno-oncology products, with a focus on precision medicine. Notable achievements include the successful development of its flagship drug, Brukinsa, which has gained recognition for its efficacy in treating various forms of blood cancer. Beigene's commitment to research and development, coupled with strategic partnerships, positions it as a key player in the competitive landscape of oncology therapeutics.
DitchCarbon Score
How does Beigene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beigene's score of 28 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Beigene's reported carbon emissions
In 2023, Beigene reported total carbon emissions of approximately 555,892,000 kg CO2e. This figure includes Scope 1 emissions of about 2,463,000 kg CO2e, primarily from stationary and mobile combustion, and Scope 2 emissions of approximately 76,485,000 kg CO2e, mainly from purchased electricity. Additionally, the company disclosed significant Scope 3 emissions, totalling around 476,965,000 kg CO2e, which encompass various categories such as purchased goods and services, capital goods, and employee commuting. Over the years, Beigene has shown fluctuations in its emissions, with a notable increase from 2022's total of approximately 274,416,000 kg CO2e. Despite this rise, the company has not set specific reduction targets or initiatives as part of its climate commitments, indicating a potential area for future focus. Beigene's emissions data reflects its operational scale and the challenges faced in reducing carbon footprints within the biopharmaceutical industry. The company continues to monitor its emissions across all scopes, aiming for transparency in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 535,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,929,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Beigene is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
